DexCom, Inc.(DXCM)

NASDAQ Global Select
Sector: Healthcare | Industry: Medical - Devices
DexCom, Inc. logo

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Latest News & Analysis

DexCom (DXCM) stock analysis: FDA scrutiny, Nanowear partnership, and market expansion impact investor strategy. Financials from Monexa AI.
Apr 9, 2025

DexCom (DXCM): FDA Warning, Nanowear Partnership, and Market Expansion

DexCom (DXCM) faces FDA scrutiny, partners with Nanowear, and expands CGM coverage. A comprehensive look at recent developments and their impact on investors.

Read more →
DexCom's Type 2 Diabetes Strategy: Navigating FDA hurdles and competition with CGM innovation. Revenue and growth analysis included.
Mar 24, 2025

DexCom (DXCM): Navigating FDA Scrutiny, Type 2 Diabetes Market, and Competitive Landscape

DexCom (DXCM) navigates FDA scrutiny, targets Type 2 diabetes market amid CGM competition. Key developments and financial analysis included.

Read more →
DexCom (DXCM) stock analysis: CGM market growth, regulatory hurdles, and financial performance insights for investors.
Mar 20, 2025

DexCom (DXCM): FDA Hurdles, European Expansion, CGM Innovation

DexCom (DXCM) navigates FDA hurdles, expands in Europe, and innovates CGM technology. Analysis of financial performance, market dynamics, and strategic initiatives.

Read more →
Dexcom (DXCM) stock analysis: FDA warning letter, market competition, and future growth prospects in the CGM landscape.
Mar 17, 2025

DexCom (DXCM): Navigating Regulatory Scrutiny and Market Competition

DexCom faces FDA scrutiny amid CGM market competition. Analysis of regulatory challenges, competitive landscape, and financial resilience.

Read more →
DexCom stock analysis: Navigating FDA scrutiny, competition, and growth opportunities in the CGM market. Stay informed on DXCM.
Mar 11, 2025

DexCom (DXCM): FDA Warning, Competition, and Market Outlook

Analysis of DexCom's challenges and opportunities in the CGM market, including an FDA warning letter, competitive pressures, and growth prospects.

Read more →
Dexcom FDA Warning Letter: Impact on DXCM stock and CGM market competition with Abbott, plus AI integration and revenue growth analysis.
Mar 10, 2025

DexCom Under Scrutiny: FDA Warning Letter, Market Impact, Growth

DexCom (DXCM) faces FDA scrutiny, market impact, and strategic growth in diabetes care. Gain insights into their response, competition, and AI integration.

Read more →
DexCom stock analysis: Recent developments, market trends, and strategic initiatives impacting DXCM, continuous glucose monitoring systems and diabetes management solutions.
Mar 3, 2025

DexCom, Inc. - Industry Impact and Market Trends Analysis

DexCom, Inc. navigates a dynamic healthcare landscape with AI-driven CGM technology. Revenue growth faces margin pressures amid competition and market volatility.

Read more →
DexCom (DXCM) Q4 2024 Analysis: Stelo Launch, AI Integration, and Future CGM Growth
Feb 28, 2025

DexCom (DXCM): Q4 Performance, Stelo Launch, and the Future of CGM

DexCom's Q4 results show revenue growth but an earnings miss. Stelo's launch and AI integration are key. Analyst sentiment is cautiously optimistic amid competition.

Read more →
DexCom (DXCM) stock analysis: CGM market trends, Stelo OTC launch, AI integration, and DexCom's future growth strategies.
Feb 26, 2025

DexCom (DXCM) Analysis: CGM Market, Stelo Launch, and Future Growth

DexCom (DXCM) navigates the competitive CGM market with mixed Q4 results, focusing on innovation and strategic partnerships for future growth. Stelo OTC CGM launch is key.

Read more →
DexCom CGM: Understand competition, innovation, and future prospects in the CGM market. Analyst insights, financial health, and market trends.
Feb 25, 2025

DexCom (DXCM): Navigating Competition and Innovation

A comprehensive analysis of DexCom (DXCM), covering Q4 2024 performance, competition, GLP-1 impacts, AI, global expansion, and analyst views. Key takeaways for investors and analysts.

Read more →
DexCom's CGM market position: Q4 2024 earnings analysis, revenue growth, and technological innovation in diabetes management. #CGM #DexCom #DiabetesTech
Feb 21, 2025

DexCom CGM Market Analysis: Growth, Competition, and Innovation (DXCM)

DexCom (DXCM) Q4 2024 saw +8.00% revenue growth with an EPS miss amid competitive pressures and global expansion. Cautious optimism drives future strategies.

Read more →
Dexcom G7 CGM system analysis: review, financial performance, and market position. Continuous glucose monitoring technology.
Feb 21, 2025

Dexcom Q4 2024 Earnings: Analyzing CGM Market Trends

Dexcom's Q4 2024 performance shows revenue growth but an EPS miss. This report analyzes the CGM market trends, competition, and strategic initiatives.

Read more →
Close-up of a continuous glucose monitor on a person's arm in a medical setting.
Feb 18, 2025

Dexcom Q4 2024: Revenue Up, Earnings Down, What's Next?

An in-depth analysis reveals Dexcom's Q4 2024 revenue growth, earnings challenges, competitive pressures, and strategic innovation.

Read more →